

Terri Madison, PhD, MPH

President, i3 Drug Safety

Dr. Madison is President of i3 Drug Safety, joining i3 Drug Safety as its founding leader in 2005. Terri received her doctorate in epidemiology from the University of Michigan, and a MPH from the University of Michigan School of Public Health. Prior to her current role, Dr. Madison served as Sr. Vice President of Global Operations at i3 Statprobe, a global data services CRO. With over 20 years of biopharmaceutical industry experience, including 8 years at Parke-Davis Pharmaceutical Research and 11 years at STATPROBE, Terri has substantial experience in data collection, analysis, and reporting across multiple therapeutic areas in all phases of research.

In her current role, Dr. Madison's responsibilities include business and scientific leadership for safety services provided by the pharmacovigilance and clinical epidemiology teams. Dr. Madison often serves in a consulting capacity to both internal and external clients; her core areas of research interest and expertise includes pregnancy surveillance; risk management; and the design, conduct, and analysis of observational cancer studies, where she has worked with both state and national cancer registries to evaluate both social and biological factors associated with prognosis.

John D. Seeger, PharmD, DrPH

Senior Scientist, i3 Drug Safety

John D. Seeger is a pharmacoepidemiologist who has been working with i3 Drug Safety since 2001 and has conducted numerous studies that have addressed regulatory drug safety issues involving a wide array of drugs and disease conditions, largely within an insurance claims environment. Dr. Seeger received a PharmD from the University of Arizona, a MPH from the University of Michigan, and a DrPH from the Harvard School of Public Health. Originally trained as a clinical pharmacist, Dr. Seeger spent three years on the faculty of the University of Illinois at Chicago where he also completed a residency in pharmacy practice. Dr. Seeger's research interest is in predictors of drug therapy and research methods that incorporate these predictors. He has worked extensively with propensity scores and related methods that seek to mitigate confounding by modeling drug therapy as a function of covariates, and he teaches a course on propensity scores at Harvard School of Public Health. He has authored or co-authored more than 30 articles in the peer-reviewed medical literature.